# A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)

Study · id `cardio:ct-nct01618669` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01618669](<https://clinicaltrials.gov/study/NCT01618669>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01618669

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1147 participants.

## Technical summary

Registry record NCT01618669. Randomized; no masking. Start 2012-06 (registry gives no type); primary completion 2014-12 (actual). Results posted on 2016-02-08.

## Key facts

- Design: Interventional study; randomized; no masking
- Phase: Phase 3
- Enrolled: 1147 participants (enrolled count; ClinicalTrials.gov record NCT01618669, source copy `cardio:ctgov-nct01618669-2016-02-08`, retrieved 2026-10-26)
- Start date: 2012-06 (registry gives no type) (ClinicalTrials.gov record NCT01618669, source copy `cardio:ctgov-nct01618669-2016-02-08`, retrieved 2026-10-26)
- Primary completion: 2014-12 (actual) (ClinicalTrials.gov record NCT01618669, source copy `cardio:ctgov-nct01618669-2016-02-08`, retrieved 2026-10-26)
- Completion: 2014-12 (actual) (ClinicalTrials.gov record NCT01618669, source copy `cardio:ctgov-nct01618669-2016-02-08`, retrieved 2026-10-26)
- Results first posted: 2016-02-08 (ClinicalTrials.gov record NCT01618669, source copy `cardio:ctgov-nct01618669-2016-02-08`, retrieved 2026-10-26)
- Countries: United States; Argentina; Peru; Puerto Rico (ClinicalTrials.gov record NCT01618669, source copy `cardio:ctgov-nct01618669-2016-02-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01618669-2016-02-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)
- Acronym: EXERRT
- Condition: Coronary Artery Disease (CAD)
- Intervention (Drug): Regadenoson
- Intervention (Procedure): Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
- Lead sponsor: Astellas Pharma Global Development, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)

## Provenance

Content hash: ce0c4f7452efdecb16de36eb568282ca33fa72063b6c940f53a9646710ea2bb7
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
